Scinai Immunotherapeutics Ltd ADR (SCNI)

$2.27 -0.22 (-8.84%)
Market Cap 2.49M
Revenue (ttm) 660,000.00
Net Income (ttm) 4.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 727.27%
Debt to Equity Ratio 0.03
Volume 336,800
Avg Vol 465,050
Day's Range N/A - N/A
Shares Out 1.00M
Stochastic %K 21%
Beta 2.04
Analysts Strong Buy
Price Target $8.00

Company Profile

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Gottingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indic...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 8 930 2529
Fax: 972 8 930 2531
Address:
Jerusalem BioPark, 2nd floor Hadassah Ein Kerem Campus, Jerusalem, Israel
Justjohnn
Justjohnn Jul. 2 at 5:21 PM
$SCNI What is with the 4 or 5am spikes?
1 · Reply
TA_Kongen
TA_Kongen Jul. 2 at 12:11 PM
$GITS $SCNI Pop candidates today. Hints of algos potentially providing liquidity.
1 · Reply
SmartBetting
SmartBetting Jul. 2 at 12:09 PM
$SCNI time to start. cheer up to maindriver!
0 · Reply
SpartanVI
SpartanVI Jul. 2 at 11:25 AM
$SCNI $BGLC $ELWS Scni about to go
1 · Reply
SmartBetting
SmartBetting Jul. 2 at 10:27 AM
$SCNI showtime is coming.
0 · Reply
SpartanVI
SpartanVI Jul. 2 at 10:07 AM
$SCNI another cheap under 1mil floater Could go like $BGLC $ELWS Known runner 2$+ cheap with this float
1 · Reply
SpartanVI
SpartanVI Jul. 2 at 9:20 AM
$SCNI watching
0 · Reply
bigmoneygrip9
bigmoneygrip9 Jul. 2 at 9:15 AM
$SCNI any news ??
0 · Reply
SmartBetting
SmartBetting Jul. 2 at 9:03 AM
$SCNI goodmorning~goodluck.
0 · Reply
_www_larval_com_
_www_larval_com_ Jul. 1 at 7:53 PM
$BMNR 8%[39%] $SCNI 7%[10%] $OBLG 6%[15%] $ECX -4%[5%] $SCAG -4%[-55%] most notable movement into the final minutes of trading.
0 · Reply
Latest News on SCNI
Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Jun 12, 2025, 8:00 AM EDT - 20 days ago

Scinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

Jun 5, 2025, 9:00 AM EDT - 27 days ago

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

May 30, 2025, 7:00 AM EDT - 4 weeks ago

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

Scinai Announces Annual Financial Results for 2024

May 7, 2025, 4:01 PM EDT - 2 months ago

Scinai Announces Annual Financial Results for 2024

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

May 1, 2025, 7:00 AM EDT - 2 months ago

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Mar 27, 2025, 9:25 AM EDT - 3 months ago

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

Mar 17, 2025, 7:00 AM EDT - 3 months ago

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Mar 5, 2025, 7:30 AM EST - 4 months ago

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Jan 6, 2025, 7:31 AM EST - 6 months ago

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Dec 16, 2024, 9:25 AM EST - 7 months ago

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Dec 5, 2024, 8:25 AM EST - 7 months ago

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

Nov 27, 2024, 8:00 AM EST - 7 months ago

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Nov 22, 2024, 7:15 AM EST - 7 months ago

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Oct 31, 2024, 6:59 AM EDT - 8 months ago

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

Sep 16, 2024, 7:00 AM EDT - 10 months ago

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

Sep 9, 2024, 11:12 AM EDT - 10 months ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

Scinai Regains Full Compliance with Nasdaq Listing Requirements

Aug 29, 2024, 6:31 AM EDT - 10 months ago

Scinai Regains Full Compliance with Nasdaq Listing Requirements

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Aug 21, 2024, 8:45 AM EDT - 11 months ago

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript

Aug 20, 2024, 2:28 PM EDT - 11 months ago

Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Aug 20, 2024, 9:30 AM EDT - 11 months ago

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Aug 15, 2024, 7:00 AM EDT - 11 months ago

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

Aug 13, 2024, 7:00 AM EDT - 11 months ago

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Jul 23, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results

Jul 15, 2024, 12:31 PM EDT - 1 year ago

Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

Jul 15, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Jul 8, 2024, 8:14 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Jul 3, 2024, 9:32 AM EDT - 1 year ago

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Jul 2, 2024, 8:12 AM EDT - 1 year ago

Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

Jun 13, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

Jun 7, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

May 24, 2024, 4:01 PM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

May 15, 2024, 4:01 PM EDT - 1 year ago

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal

May 6, 2024, 9:21 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

Scinai leadership to attend BIO-Europe Spring 2024

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Scinai leadership to attend BIO-Europe Spring 2024

Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024

Feb 29, 2024, 8:45 AM EST - 1 year ago

Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

Feb 13, 2024, 7:00 AM EST - 1 year ago

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

Jan 25, 2024, 10:26 AM EST - 1 year ago

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Jan 4, 2024, 4:01 PM EST - 1 year ago

Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Scinai Immunotherapeutics CEO Issues Letter to Shareholders

Jan 4, 2024, 6:15 AM EST - 1 year ago

Scinai Immunotherapeutics CEO Issues Letter to Shareholders

Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Dec 29, 2023, 9:21 AM EST - 1 year ago

Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9

Dec 27, 2023, 7:15 AM EST - 1 year ago

Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9

Scinai Announces Promising Results in a Psoriatic Human Skin Model

Dec 12, 2023, 7:26 AM EST - 1 year ago

Scinai Announces Promising Results in a Psoriatic Human Skin Model

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug

Dec 11, 2023, 8:11 AM EST - 1 year ago

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug

European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031

Nov 29, 2023, 9:25 AM EST - 1 year ago

European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031

Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule

Nov 20, 2023, 7:30 AM EST - 1 year ago

Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule

Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit

Nov 6, 2023, 7:30 AM EST - 1 year ago

Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit

Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance

Nov 3, 2023, 4:30 PM EDT - 1 year ago

Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance

European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai's recent strategic pivot

Oct 31, 2023, 9:00 AM EDT - 1 year ago

European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai's recent strategic pivot

Justjohnn
Justjohnn Jul. 2 at 5:21 PM
$SCNI What is with the 4 or 5am spikes?
1 · Reply
TA_Kongen
TA_Kongen Jul. 2 at 12:11 PM
$GITS $SCNI Pop candidates today. Hints of algos potentially providing liquidity.
1 · Reply
SmartBetting
SmartBetting Jul. 2 at 12:09 PM
$SCNI time to start. cheer up to maindriver!
0 · Reply
SpartanVI
SpartanVI Jul. 2 at 11:25 AM
$SCNI $BGLC $ELWS Scni about to go
1 · Reply
SmartBetting
SmartBetting Jul. 2 at 10:27 AM
$SCNI showtime is coming.
0 · Reply
SpartanVI
SpartanVI Jul. 2 at 10:07 AM
$SCNI another cheap under 1mil floater Could go like $BGLC $ELWS Known runner 2$+ cheap with this float
1 · Reply
SpartanVI
SpartanVI Jul. 2 at 9:20 AM
$SCNI watching
0 · Reply
bigmoneygrip9
bigmoneygrip9 Jul. 2 at 9:15 AM
$SCNI any news ??
0 · Reply
SmartBetting
SmartBetting Jul. 2 at 9:03 AM
$SCNI goodmorning~goodluck.
0 · Reply
_www_larval_com_
_www_larval_com_ Jul. 1 at 7:53 PM
$BMNR 8%[39%] $SCNI 7%[10%] $OBLG 6%[15%] $ECX -4%[5%] $SCAG -4%[-55%] most notable movement into the final minutes of trading.
0 · Reply
_www_larval_com_
_www_larval_com_ Jul. 1 at 7:47 PM
$SCNI has reverted -11% lower to 2% (~428Kv) in the last few minutes, follow for more volatility.
0 · Reply
Richard_Roma
Richard_Roma Jul. 1 at 7:24 PM
$SCNI another pump and dump for bagholders.
2 · Reply
DGains
DGains Jul. 1 at 7:08 PM
$SCNI Night Night.. 🌝💹 $NXTT Next Flight 🛫💵 $SHPH Shuttle Service 💹 $PMAX Let’s MAX OUT! 🚀🌙🌕
0 · Reply
jParkz
jParkz Jul. 1 at 7:00 PM
News Expected earnings - Scinai Immunotherapeutics Ltd. https://marketwirenews.com/news-releases/expected-earnings-scinai-immunotherapeutics-ltd--8851574798819440.html $SCNI
0 · Reply
CrumbEater
CrumbEater Jul. 1 at 6:04 PM
$SCNI we moving
0 · Reply
Zohan_69
Zohan_69 Jul. 1 at 5:36 PM
$SCNI 🔥 NEWS 👉🏼 Scinai Immunotherapeutics received approval from the Italian government to acquire Pincell. 👉🏼 The acquisition strengthens Scinai's strategic focus on products for the treatment of inflammation and immunology. and 🔥 Low float: 800,000 🔥 Market capitalization: USD 1.90 million 🔥 Net income for 2024 was USD 4.8 million compared to a net loss of USD 6.5 million for 2023 https://x.com/scinai/status/1928433154190155807?s=46
4 · Reply
Zohan_69
Zohan_69 Jul. 1 at 5:34 PM
$SCNI 🔥 NEWS June 26, 2025 💪🏼 👉🏼 Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Highlights PC111 Breakthrough After Scientist Wins Top Italian Dermatology Award 👉🏼Scinai has expanded its product pipeline with the planned acquisition of Pincell Srl, an Italian biotechnology company developing PC111. The acquisition has been approved by regulators and is expected to add another high-quality orphan drug candidate to the company's diversified R&D portfolio. https://www.biomedwire.com/biomednewsbreaks/biomednewsbreaks-scinai-immunotherapeutics-ltd-nasdaq-scni-highlights-pc111-breakthrough-after-scientist-wins-top-italian-dermatology-award/
5 · Reply
Zohan_69
Zohan_69 Jul. 1 at 5:29 PM
$SCNI 🔥 NEWS 👉🏼 Scinai (SCNI) Gains – Biotech Investors Invest in Scinai's Dual-Revenue Model 👉🏼 This hybrid approach offers Scinai both innovation-driven growth and a non-dilutive revenue stream that supports its long-term pipeline ambitions. 👉🏼 This CDMO segment is growing rapidly. Revenues expected to reach $2 million in 2025
2 · Reply
Zohan_69
Zohan_69 Jul. 1 at 5:26 PM
$SCNI 🔥 NEWS 🔥 CEO Amir Reichman to participate in the BIO International Convention 2025 (June 16-19, Boston) 👉🏼 At BIO 2025, Mr. Reichman will hold meetings with pharmaceutical industry executives, institutional investors, and CDMO clients to present Scinai's recent successes and discuss upcoming partnership opportunities. 👉🏼 CDMO business growing rapidly; revenue expected to reach $2 million in 2025. 👉🏼 Recent SEPA financing increases operational flexibility, with no warrants, fees, or additional dilution mechanisms. The proceeds strengthen Scinai's balance sheet and provide additional capital for CDMO growth and R&D programs. 👇🏼👇🏼 read the 👇🏼👇🏼 NEWS https://finance.yahoo.com/news/scinai-highlights-funding-cdmo-growth-120000871.html
1 · Reply
Justjohnn
Justjohnn Jun. 27 at 6:31 PM
$SCNI Whatcos going on with the Ask side level 2? Shifting and bouncing all over the place
0 · Reply
NetworkNewsWire
NetworkNewsWire Jun. 26 at 7:25 PM
BioMedNewsBreaks – $SCNI Highlights PC111 Breakthrough After Scientist Wins Top Italian Dermatology Award https://ibn.fm/QhZ6k
4 · Reply
CrumbEater
CrumbEater Jun. 24 at 7:19 PM
$SCNI we have some movement!!
0 · Reply